How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

632 results for

Wart Immune Therapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Recommendations for reducing the risk of viral transmission during fertility treatment with the use of autologous gametes: a committee opinion

acategoryXmedicationandhasproventeratogenicandem- bryocidalpropertiesinallanimalspecies.Ribaviriniscontra- indicated in the male partner of a pregnant female and in pregnancy. Because the drug is believed to cause new muta- tions, it is recommended that: two forms of contraception be used during therapy; pregnancy testing be performed monthly; and pregnancy be avoided for the ?rst six months after discontinuation of therapy in either partner. Although few women have been studied, there does not appear to be an increase in adverse pregnancy (...) Recommendations for reducing the risk of viral transmission during fertility treatment with the use of autologous gametes: a committee opinion Recommendations for reducing the risk of viral transmission during fertility treatment with the use of autologous gametes: a committee opinion The Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Thisdocumentprovidesstrategies,basedonscienti

2013 Society for Assisted Reproductive Technology

182. Anal cancer screening ? A case for screening anal paps

is likely to be cost effective. The current New York State AIDS Institute guidelines now recommends targeted anal PAP for HIV infected MSM, individuals with a history of anogenital warts, and for women with a history of abnormal cervical or vulvar histology. Silverberg MJ, Lau B, Justice AC, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis. 2012 Apr; 54(7):1026-34. Dr. Nelson Sanchez is a former resident at NYU Langone Medical Center (...) pose a significant barrier that dissuades clinical discussion of the test. In addition, insurance coverage for anal pap smears is very limited. Another issue that arises from anal cancer screening is the question of treatment. Unlike cervical dysplasia and localized cervical cancer, where large excisions or complete [8], anal dysplasia and cancer does not have comparable treatment capability or success. Current treatment modalities for anal dysplasia include topical agents, immune modulation

2013 Clinical Correlations

183. Guest Post: Who Calls the Shots?  Teens and the HPV Vaccine

Guest Post: Who Calls the Shots?  Teens and the HPV Vaccine Guest Post: Who Calls the Shots? Teens and the HPV Vaccine | Journal of Medical Ethics blog by Suchi Agrawal Paper: During my pediatric hospital medicine rotation, I stopped the team before we entered the room of our sixteen-year-old patient and her parents. “Just a reminder, the patient does not want her parents to know she was tested for gonorrhea and chlamydia.” After ensuring we were all on the same page, we continued with our (...) and individual medical benefits. The vaccine protects against human papillomavirus – a sexually transmitted infection that can cause genital warts, cervical, and oropharyngeal cancers. Thus, a vaccine protects both the individual and his or her sexual partners from preventable medical diseases. Furthermore, providers can strengthen the patient-physician relationship by establishing their role as a trusted resource for “sensitive topics” such as sexual health. This relationship is important as the major

2018 Journal of Medical Ethics blog

184. Should Physicians Offer The HPV Vaccine To Men And Boys?

State are now required to cover HPV4 for boys 9-18 years of age. As Benjamin Franklin once stated, “an ounce of prevention is worth a pound of cure.” Kevin Burns is a 4th year medical student at NYU School of Medicine Peer reviewed by Andrew Wallach, MD, Department of Medicine (GIM Div), NYU Langone Medical Center Image courtesy of Wikimedia Commons References: 1. U.S. Food and Drug Administration. Gardasil approved to prevent anal cancer. . Published December 22, 2010. Accessed January 27, 2011. 2 (...) . U.S. Food and Drug Administration. FDA approves expanded uses for Gardasil to include preventing certain vulvar and vaginal cancers. . Published September 12, 2008. Accessed January 27, 2011. 3. U.S. Food and Drug Administration. FDA approves new indication for Gardasil to prevent genital warts in men and boys. U.S. Food and Drug Administration. . Published October 16, 2009. Accessed January 27, 2011. 4. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females

2012 Clinical Correlations

185. Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency

treatment at restoring immune function to participants with X-linked severe combined immunodeficiency (XSCID) who are 2 to 40 years of age, and have significant impairment of immunity. Condition or disease Intervention/treatment Phase X-Linked Combined Immunodeficiency Diseases Biological: CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT Drug: Palifermin Drug: Busulfan Phase 1 Phase 2 Detailed Description: This study will evaluate the safety and effectiveness (...) to be negative for HIV infection by genome polymerase chain reaction (PCR) The patient must be judged by the primary evaluating physician to have a suitable family and social situation consistent with ability to comply with protocol procedures and the long-term follow-up requirements. Medical lab data (historical) of severe B cell dysfunction (low or absent immunoglobulin G [IgG] levels, failed immune response to vaccines); OR demonstrated requirement for intravenous gamma globulin (IVIG) (significant drop

2017 Clinical Trials

186. Study to Assess the Cosmetic Changes in the Facial Skin After Use of a Topical Retinoid Product in Participants With Moderate to Severe Photodamage

of a Topical Retinoid Product In Subjects With Moderate to Severe Photodamage Actual Study Start Date : September 5, 2017 Actual Primary Completion Date : April 30, 2018 Actual Study Completion Date : April 30, 2018 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Retinol Complex 0.5 During a 2-week washout period the participant will use a basic skin care regimen (SkinMedica facial cleanser (...) , crosshatched deep creases; extreme elastosis at Baseline and Week 12. A decrease in score indicates improvement. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table

2017 Clinical Trials

187. ICVT in HPV-induced Genital Lesions of Immunocompromised and Immunocompetent Patients

of the investigator based upon the results of a medical history, physical examination, ECG, chemistry, hematology. In case of immunocompromised patients including but not limited to; patients receiving immunosuppressive therapy for any reason, patients with auto-immune disease, HIV patients, transplantation patients In case of genital warts patient group(s): have at least 3 genital warts (only applicable to Study Part 1) In case of vulvar HSIL: at least one lesion that can be accurately measured in at least one (...) : Cutanea Life Sciences, Inc. Information provided by (Responsible Party): Cutanea Life Sciences, Inc. Study Details Study Description Go to Brief Summary: This study is intended to explore and evaluate the pharmacodynamics and clinical efficacy of the ionic contra-viral therapy CLS003 in immunocompromised and immunocompetent patients with benign and premalignant HPV-induced genital lesions Condition or disease Intervention/treatment Phase HPV-Induced Genital Lesions Drug: CLS003 Drug: Vehicle Phase 2

2017 Clinical Trials

188. Local Hyperthermia for the Treatment of Cervical Intraepithelial Neoplasias

could cleared HPV in more than half of the patients with plantar warts. Investigators also note the fact that in patients with multiple lesions, the clearance of the target lesion is commonly followed by clearance of other distant lesions, a phenomenon suggesting that local hyperthermia could aid in establishing a specific immune response to eliminate HPV.So the purpose of the study is to evaluation local hyperthermia in the treatment of cervical intraepithelial neoplasias grade I and II after 3 (...) of some diseases. It has been utilised in the treatment of some neoplasm, fungal and HPV infections. Investigators' study found that local hyperthermia at 44°C could cleared HPV in more than half of the patients with plantar warts. Investigators also note the fact that in patients with multiple lesions, the clearance of the target lesion is commonly followed by clearance of other distant lesions, a phenomenon suggesting that local hyperthermia could aid in establishing a specific immune response

2017 Clinical Trials

189. IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

, patients undergo surgical resection. Drug: Cyclophosphamide Given IV Drug: Indomethacin Given PO Other: Laboratory Biomarker Analysis Correlative studies Dietary Supplement: Multivitamin Given zinc-containing multivitamin PO Other Names: Geritol Vitamin Supplements (NOS) Drug: Omeprazole Given PO Other: Placebo Given via submucosal injections or SC Other Names: placebo therapy sham therapy Procedure: Therapeutic Conventional Surgery Undergo surgical resection Outcome Measures Go to Primary Outcome (...) ULN, or Clinically significant active cardiovascular disease, including a history of myocardial infarction within the past 6 months, heart failure as defined by New York Heart Association classes III or IV, and/or blood pressure greater than 160/90 mm Hg (1 repeat measure allowed no more than 5 minutes after the first measurement) History of severe allergic reaction to insect bites or stings, or to any biologic pharmaceutical product, including compounds similar to the test article Any medical

2017 Clinical Trials

190. Zinc Sulfate for Human Papillomavirus (HPV)

): Spectrum Health Hospitals Study Details Study Description Go to Brief Summary: The Human Papillomavirus (HPV) is well established as the primary causative agent in both warts and cervical cancer. Although cervical high risk HPV (hrHPV) infections have a high rate of spontaneous resolution this takes time and the infection can cause cervical cells to progress to precancerous and cancerous lesions. Zinc has been shown to play a central role in immunity. This study is to determine if oral zinc sulfate can (...) Start Date : October 24, 2017 Estimated Primary Completion Date : December 31, 2018 Estimated Study Completion Date : December 31, 2018 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Placebo Comparator: Treatment Zinc Sulfate 220mg twice daily for three months. Dietary Supplement: Zinc Sulfate Participant will take one 220mg tablet twice daily for three months. Placebo Comparator: Placebo Gelatin Placebo tablet twice

2017 Clinical Trials

191. Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence

agent (eg, capsaicin, resiniferatoxin) within 12 months of Day 1 Participant has had previous or current botulinum toxin therapy of any serotype for any urological condition Participant has had previous or current botulinum toxin therapy of any serotype for any non-urological condition within 12 weeks of Day 1 Participant has been immunized for any botulinum toxin serotype Participant has history or evidence of any pelvic or urological abnormalities, bladder surgery or disease, other than OAB (...) current or previous uninvestigated hematuria Participant has hemophilia, or other clotting factor deficiencies, or disorders that cause bleeding diathesis Participant cannot withhold any antiplatelet, anticoagulant therapy or medications with anticoagulant effects for 3 days prior to Day 1 Participant has a known allergy or sensitivity to any botulinum toxin preparation Participant has any medical condition that may put him/her at increased risk with exposure to BOTOX® including diagnosed myasthenia

2017 Clinical Trials

192. Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects

Investigator likely to require additional systemic glucocorticosteroid therapy during the study, is exclusionary. History of any clinically important drug or vaccine allergy or anaphylaxis A cluster of differentiation 4 (CD4+) lymphocyte count < 500 cell/millimeters cubed (mm^3) at Screening Positive anti-keyhole limpet hemocyanin (KLH) antibodies at Screening Previous immunization with KLH Known allergy to shellfish, KLH vaccine, or hypersensitivity to proteins foreign to the body Levels of Immunoglobulin (...) the last 3 years before Screening, even if treated Therapy for latent TB that has not been completed as per local country guidelines Positive interferon gamma release assay (IGRA) for TB unless proper treatment is documented, as described above Donation of blood (> 500 mL) or blood products within 2 months (56 days) prior to Day -1 Any medically relevant pre-existing condition that could jeopardize the safety of the participant during the trial Any participant, on the judgment of the Principal

2017 Clinical Trials

193. Gardasil Knowledge

cancers and warts. The HPV-9 vaccine includes protection from 7 strains of HPV associated with 74% of HPV related cancers. While Gardasil was approved and released in 2006, many men and women have not been vaccinated. A national immunization survey in 2011 of teens 13-17 years old noted that only 60% of girls and 40% of boys have received at least one vaccination in the series. While complete vaccination series is recommended, a recent study found that a single dose of Gardasil when compared (...) Outcome Measures : knowledge about HPV risk factors [ Time Frame: 1 year ] The survey asks about Gardasil vaccine knowledge Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information

2017 Clinical Trials

194. A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome

-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by X4 Pharmaceuticals: CXCR4 Mutation Primary immunodeficiency disorder Warts Hypogammaglobulinemia Infections Myelokathexis Human papillomavirus (HPV) Neutropenia Herpes Additional relevant MeSH terms: Layout table for MeSH terms Syndrome Immunologic Deficiency Syndromes Warts Disease Pathologic Processes Immune System Diseases Papillomavirus Infections DNA Virus Infections Virus Diseases Skin Diseases, Viral (...) Information provided by (Responsible Party): X4 Pharmaceuticals Study Details Study Description Go to Brief Summary: This natural history study is a prospective and retrospective, observational study of WHIM patients. WHIM syndrome is a rare, genetic, primary immunodeficiency disorder (a disorder in which the body's immune system does not function properly). WHIM is an acronym for some of the symptoms of the disorder - Warts, Hypogammaglobulinemia (low levels of certain antibodies), Infections

2017 Clinical Trials

195. Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults

of and/or unwillingness to abstain from the following medications during study participation: Heparin, including Lovenox® Warfarin Plavix® (clopidogrel bisulfate) Aspirin (greater than 81 mg) Non-steroidal anti-inflammatory drugs (NSAIDS) Any other drugs that are associated with increased likelihood of bleeding CYP3A inducer(s) and/or inhibitor(s) as specified in the MTN-026 Study-Specific Procedures (SSP) Manual Hormone-replacement therapy in tablet, injectable or gel form Known adverse reaction to any (...) : September 20, 2018 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Dapivirine gel Participants will receive a single dose of dapivirine gel rectally, followed by 7 daily doses of dapivirine gel to be administered under direct observation in the clinic. Drug: Dapivirine gel Dapivirine gel (0.05%); administered rectally Placebo Comparator: Placebo gel Participants will receive a single dose of placebo gel

2017 Clinical Trials

196. Committee Opinion No. 704 Summary: Human Papillomavirus Vaccination. (Abstract)

doses. Compared with many other countries, HPV vaccination rates in the United States are unacceptably low. The U.S. Food and Drug Administration has approved three vaccines that are effective at preventing HPV infection. These vaccines cover 2, 4, or 9 HPV serotypes, respectively. Safety data for all three HPV vaccines are reassuring. The HPV vaccines are recommended for girls and boys aged 11-12 years and can be given to females and males up to age 26 years. The Advisory Committee on Immunization (...) Practices and the American College of Obstetricians and Gynecologists recommend routine HPV vaccination for girls and boys at the target age of 11-12 years (but it may be given from the age of 9 years) as part of the adolescent immunization platform in order to help reduce the incidence of anogenital cancer and genital warts associated with HPV infection. Obstetrician-gynecologists and other health care providers should stress to parents and patients the benefits and safety of HPV vaccination and offer

2017 Obstetrics and Gynecology

197. Committee Opinion No. 704: Human Papillomavirus Vaccination. (Abstract)

. Compared with many other countries, HPV vaccination rates in the United States are unacceptably low. The U.S. Food and Drug Administration has approved three vaccines that are effective at preventing HPV infection. These vaccines cover 2, 4, or 9 HPV serotypes, respectively. Safety data for all three HPV vaccines are reassuring. The HPV vaccines are recommended for girls and boys aged 11-12 years and can be given to females and males up to age 26 years. The Advisory Committee on Immunization Practices (...) and the American College of Obstetricians and Gynecologists recommend routine HPV vaccination for girls and boys at the target age of 11-12 years (but it may be given from the age of 9 years) as part of the adolescent immunization platform in order to help reduce the incidence of anogenital cancer and genital warts associated with HPV infection. Obstetrician-gynecologists and other health care providers should stress to parents and patients the benefits and safety of HPV vaccination and offer HPV vaccines

2017 Obstetrics and Gynecology

198. CD4+FOXP3+ regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy. (Abstract)

the immunosuppression in large genital warts. Here, we further report that low-dose cyclophosphamide (CY), a conventional chemotherapy drug, can effectively prevent the recurrence of large CA in clinical patients after laser therapy. Surprisingly, although 9 out of 52 patients recur six weeks after the combination treatment, the re-administration of low-dose CY alone completely eliminates most recurred lesions. We provide evidence that low-dose CY not only depletes patients' Treg cells and enhances function of HPV (...) CD4+FOXP3+ regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy. Condylomata acuminata (CA) caused by human papillomavirus (HPV) is a common sexually transmitted disease with half a million new cases diagnosed in the United States per year and the annual increase in incidence in China. Recurrence is a major challenge for CA treatment. Recently, we demonstrated that FOXP3(+) regulatory T (Treg) cells mediate

2010 Clinical immunology (Orlando, Fla.) Controlled trial quality: uncertain

199. Canadian clinical practice guidelines for acute and chronic rhinosinusitis

, bacteriology, and standard specialist treatment strategies, an assessment of therapies prescribed in Canada for CRS has shown that medications prescribed for CRS exactly paralleled those prescribed for ARS [ ]. The incidence of bacterial rhinosinusitis is difficult to obtain precisely given that not all patients will seek medical help. In the United States in 2007, ARS affected 26 million individuals and was responsible for 12.9 million office visits [ ]. Although no specific Canadian data is available (...) and bacterial sinusitis. Vaccines and prophylactic antibiotic therapy are of no benefit. Moderate Strong 22: Allergy testing or in-depth assessment of immune function is not required for isolated episodes but may be of benefit in identifying contributing factors in individuals with recurrent episodes or chronic symptoms of rhinosinusitis. Moderate Strong Chronic Rhinosinusitis 23 : CRS is diagnosed on clinical grounds but must be confirmed with at least 1 objective finding on endoscopy or computed

2011 CPG Infobase

200. Unusual Cancers of Childhood Treatment (PDQ®): Health Professional Version

Unusual Cancers of Childhood Treatment (PDQ®): Health Professional Version Unusual Cancers of Childhood Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. PDQ Cancer Information Summaries (...) , although the overall incidence of childhood cancer has been slowly increasing since 1975.[ ] Referral to medical centers with multidisciplinary teams of cancer specialists experienced in treating cancers that occur in childhood and adolescence should be considered for children and adolescents with cancer. This multidisciplinary team approach incorporates the skills of the primary care physician, pediatric surgeons, radiation oncologists, pediatric medical oncologists/hematologists, rehabilitation

2016 PDQ - NCI's Comprehensive Cancer Database

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>